Comparative Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents Against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2017 Nov 22

PMID 29158284

Citations 9

Authors

Ellie J C Goldstein

Diane M Citron

Kerin L Tyrrell

Eliza Leoncio

C Vreni Merriam

Affiliations

Soon will be listed here.

Abstract

Relebactam is an important beta-lactamase inhibitor for certain aerobic organisms, but alone it has no antianaerobic activity, with most anaerobes having MICs of ≥32 μg/ml with the exception of a very few strains. There was no enhancement or antagonism of imipenem activity with the addition of relebactam, including activity against imipenem-resistant strains. The relebactam-imipenem combination had excellent overall activity against the anaerobes tested.

Citing Articles

New antibiotics for Gram-negative pneumonia.

Bassetti M, Magne F, Giacobbe D, Bini L, Vena A Eur Respir Rev. 2022; 31(166).

PMID: 36543346 PMC: 9879346. DOI: 10.1183/16000617.0119-2022.

Cefmetazole Resistance Mechanism for Including ESBL-Producing Strains.

Ito R, Kawamura M, Sato T, Fujimura S Infect Drug Resist. 2022; 15:5867-5878.

PMID: 36237294 PMC: 9553235. DOI: 10.2147/IDR.S382142.

The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms.

Dingle T, Pitout J J Clin Microbiol. 2022; 60(7):e0080721.

PMID: 35387484 PMC: 9297814. DOI: 10.1128/jcm.00807-21.

Overview of Changes to the Clinical and Laboratory Standards Institute M100, 31st Edition.

Humphries R, Bobenchik A, Hindler J, Schuetz A J Clin Microbiol. 2021; 59(12):e0021321.

PMID: 34550809 PMC: 8601225. DOI: 10.1128/JCM.00213-21.

New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams.

Vazquez-Ucha J, Arca-Suarez J, Bou G, Beceiro A Int J Mol Sci. 2020; 21(23).

PMID: 33291334 PMC: 7731173. DOI: 10.3390/ijms21239308.

References

Hirsch E, Ledesma K, Chang K, Schwartz M, Motyl M, Tam V . In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012; 56(7):3753-7. PMC: 3393460. DOI: 10.1128/AAC.05927-11. View

Snydman D, Jacobus N, McDermott L . In Vitro Evaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species. Antimicrob Agents Chemother. 2016; 60(10):6393-7. PMC: 5038300. DOI: 10.1128/AAC.01125-16. View

Lob S, Hackel M, Kazmierczak K, Young K, Motyl M, Karlowsky J . Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program). Antimicrob Agents Chemother. 2017; 61(6). PMC: 5444184. DOI: 10.1128/AAC.02209-16. View